3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
3
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colonic Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Magnetic Resonance Spectroscopy
5
Iodine-131
3
Fluorodeoxyglucose F18
3
trametinib
2
pazopanib
2
belinostat
2
Vemurafenib
2
Trastuzumab
2
Specimen Handling
2
Sirolimus
2
Paclitaxel
2
Fluorouracil
2
FAPI-46
2
Docetaxel
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Biopsy
2
Bevacizumab
2
Azacitidine
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
romidepsin
1
pembrolizumab
1
naporafenib
1
mercaptoundecahydrododecaborate
1
fludarabine phosphate
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Thyroid Neoplasms
×
naporafenib
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled